• CXCR4 Biology and Therapy Sequencing in WM

  2026-10-18

  The cited 2021 review examined how MYD88 and CXCR4 genomic status could inform therapy selection and sequencing in Waldenström macroglobulinemia (WM). It identified mavorixafor as a CXCR4-directed agent of interest, but did not present efficacy data for mavorixafor or establish that any particular commercial formulation was used. The strongest evidence discussed concerned BTK inhibitors and chemoimmunotherapy, while the rationale for CXCR4 antagonism remained an emerging, biomarker-linked therapeutic hypothesis.

• 7-Dehydrocholesterol: Mechanism and Evidence Scope

  2026-10-17

  7-dehydro Cholesterol, also called 7-dehydrocholesterol or 7-DHC, is described by APExBIO as an endogenous sterol intermediate, a DHCR7 substrate, and a UVB-responsive precursor in the vitamin D3 pathway. The available product information supports a conceptual overview of cholesterol biosynthesis, photobiology, and oxidation-sensitive lipid research, but it does not establish biological performance, study outcomes, or supplier-specific validation in a matched research paper.

• Ibuprofen: Documented Mechanism and Evidence Scope

  2026-10-16

  APExBIO identifies Ibuprofen, or 2-[4-(2-methylpropyl)phenyl]propanoic acid, as a non-steroidal anti-inflammatory drug and describes COX-1 and COX-2 inhibition alongside several cellular and animal-model observations. Because no identity-matched paper, methods, effect estimates, or independent validation are available in the supplied material, these claims are best treated as product-description evidence rather than an established research literature.

• Docosatrienoic Acid: Evidence and Scope

  2026-10-16

  The APExBIO listing identifies Docosatrienoic Acid as product C3255, but the available product information provides no description, structural specification, mechanism, assay context, or identity-matched research evidence. Accordingly, this overview defines what can and cannot be concluded without attributing findings from other fatty acids or related compounds.

• PDGF-BB: Identity, Mechanism, and Evidence Scope

  2026-10-15

  APExBIO’s product description defines murine recombinant PDGF-BB as a non-glycosylated, E. coli-expressed PDGF-BB homodimer with reported receptor context and dose-dependent activity in BALB/c 3T3 cells. Those claims support a product-identity and measurement overview, but not an independent assessment of mechanism, cross-model potency, or therapeutic relevance.

• BCIP/NBT AP Kit: Evidence and Scope

  2026-10-15

  The Alkaline Phosphatase Substrate Test Kit, SKU K4151, is documented by APExBIO as a BCIP/NBT chromogenic system for visualizing alkaline phosphatase activity. Its described chemistry supports a qualitative color-development principle, but no identity-matched research paper or independent performance dataset was provided; application-specific sensitivity, selectivity, reproducibility, quantitative validity, and clinical relevance therefore remain unverified.

• When Context Changes What an MMP9 Result Means

  2026-10-14

  The same MMP9-related result can signify different biology depending on the model, perturbation, and readout. In a recent mouse study, Adamtsl3 loss in parvalbumin interneurons was linked to perineuronal-net disruption and renewed adult visual-cortex plasticity. That mechanistic context is distinct from the tumor metastasis, angiogenesis, and cerebral-ischemia contexts used to describe SB-3CT. The distinction matters: a gelatinase inhibitor may be conceptually relevant to the pathway without being evidence that a particular commercial material was used, selective in the relevant tissue, or capable of reproducing the reported phenotype.

• Bufalin and CENPA: What HCC Evidence Shows

  2026-10-14

  A pre-proof study links Bufalin with reduced CENPA expression, glycolytic activity, and migratory behavior in hepatocellular carcinoma models. The findings are mechanistically suggestive but remain preliminary: computational docking, cell-based assays, and pilot xenograft staining do not establish direct binding, clinical efficacy, or safety.

• PI Nanoliposomes and Cellular Immunity

  2026-10-13

  A source-grounded editorial overview of a 2026 Journal of Controlled Release study proposing phosphatidylinositol-based nanoliposomes as self-adjuvanting, endoplasmic-reticulum-targeting vaccine carriers. The reported mouse findings suggest stronger CD8 T-cell responses and tumor control than MF59-adjuvanted ovalbumin, while the supplied evidence remains limited by its condensed, pre-proof format and lack of detailed quantitative results.

• Hoechst 33258 in KRas Tumor Mechanobiology

  2026-10-13

  A source-grounded overview of Hoechst 33258 as a DNA-imaging reagent and of reported links between KRas transfer, tunneling nanotubes, and tumor-cell mechanics. The evidence supports a mechanistic hypothesis in cell-based models, but does not establish clinical utility or prove that membrane mechanics alone drive metastasis.

• 7-dehydro Cholesterol and Antiviral Fish Biology

  2026-10-12

  A 2026 Aquaculture Reports study identified dhcr7 as a candidate genetic determinant of grass carp resistance to GCRV-II. The findings connect cholesterol biosynthesis with antiviral immunity in vivo, while leaving important questions about mechanism, long-term fitness, strain breadth and applicability beyond the studied fish model.

• Cisapride and Deep-Learning Cardiotoxicity Evidence

  2026-10-12

  An evidence-bounded overview of Grafton et al.’s iPSC-cardiomyocyte screen, its reported cardiotoxicity signals, and what the study does—and does not—show about Cisapride (R 51619).

• Drug Response Metrics in Cancer Cell Models

  2026-10-10

  Hannah R. Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework that separates growth inhibition from cell killing and emphasizes their different proportions and timing, improving interpretation of in vitro drug-response studies.

• Lactylation–NSUN2 Axis Drives Pancreatic Cancer PNI

  2026-10-09

  A 2026 Theranostics study identifies NSUN2 K692 lactylation as a mechanistic link between lactate accumulation, RNA m5C modification, and perineural invasion in pancreatic ductal adenocarcinoma. Its multi-level evidence supports a lactate–NSUN2–m5C–CDCP1/STC1 axis, while the findings remain primarily preclinical and require further validation in clinically representative cohorts and therapeutic studies.

• Calcitriol and VDR Signaling: Research Evidence

  2026-10-09

  Calcitriol, or 1,25-dihydroxy vitamin D3, is being studied as a regulator of vitamin D receptor signaling across reproductive, immune, skeletal, and cancer biology. Recent in vitro evidence links this pathway to endometrial stromal-cell decidualization, while broader claims involving cytokines, Hedgehog signaling, and clinical outcomes remain context-dependent and require stronger primary-source support.

8671 records 1/579 page Next 12345 下5页 Last page